Stemline files Elzonris marketing application Europe for BPDCN; shares up 2%  Seeking Alpha

Stemline Therapeutics (STML +2.1%) has filed a marketing application in Europe seeking approval for ELZONRIS (tagraxofusp) for blastic plasmacytoid …

Source: Marketing feed